Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to discovering and developing innovative targeted therapies that address the unmet needs of cancer patients. The company leverages its proprietary product engine to target frontier oncology pathways, with a strong focus on the RAS and mTOR signaling pathways, which are crucial for cancer growth and survival. Revolution Medicines’ approach draws inspiration from nature and evolution, harnessing insights from natural products to guide the discovery and development of small molecules that modulate key cancer targets.
The company’s research and development pipeline features several promising candidates, including RMC-4630, a SHP2 inhibitor, and a portfolio of RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805. These novel therapies aim to inhibit the active form of RAS proteins, which are common drivers in numerous cancer types. Revolution Medicines is also advancing the SOS1 and 4EBP1/mTORC1 programs, which hold significant potential in combination treatment strategies.
Recent achievements highlight the company’s progress in clinical development. Notably, the RMC-6236 Phase 1/1b trial demonstrated promising clinical activity and a favorable safety profile in patients with advanced solid tumors harboring KRAS mutations. The trial results showed an objective response rate of 38% in non-small cell lung cancer (NSCLC) and 20% in pancreatic ductal adenocarcinoma (PDAC), with disease control rates of 85% and 87%, respectively.
In October 2023, Revolution Medicines announced a pivotal milestone with the merger with EQRx, Inc., enhancing its financial position and enabling further investment in its clinical programs. The merger is expected to add approximately $1.1 billion in net cash proceeds, supporting the advancement of their RAS(ON) and RAS Companion Inhibitors. Dr. Sandra Horning, a renowned oncologist and former Genentech executive, joined the board of directors, bringing invaluable experience to the company.
Revolution Medicines continues to engage the scientific community and stakeholders through presentations at major conferences and investor webcasts. The company remains committed to advancing its robust pipeline of oncology therapies, aiming to revolutionize the treatment landscape for RAS-addicted cancers and improve outcomes for cancer patients worldwide.
Revolution Medicines, a clinical-stage oncology company focused on targeted therapies for RAS-addicted cancers, will feature CEO Mark A. Goldsmith in a fireside chat at the 22nd Annual Needham Healthcare Conference from April 17-20, 2023. The chat is scheduled for 3:00 p.m. Eastern on April 20, 2023, and will be held virtually with a webcast available. Interested parties can access the live presentation and the subsequent replay on the company’s website for at least 14 days after the event.
The company specializes in developing RAS(ON) Inhibitors aimed at various oncogenic RAS protein variants, with RMC-6236 and RMC-6291 currently in clinical development. Additional pipeline candidates target other RAS mutations and include RAS Companion Inhibitors for combination therapies. For further details, visit Revolution Medicines Events.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.
Revolution Medicines, Inc. (Nasdaq: RVMD) has successfully closed an underwritten public offering, raising $345 million by selling 15,681,818 shares of common stock at a price of $22.00 per share. The underwriters fully exercised their option to purchase additional shares, contributing 2,045,454 shares to the total. The offering was managed by J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities. The registration statement was filed on March 2, 2021, and this transaction is crucial for funding the company's research and development of targeted therapies for RAS-addicted cancers.
Revolution Medicines has announced a public offering of 13,636,364 shares of common stock at $22.00 each, aiming to raise approximately $300 million. All shares are offered by the company, with an additional option for underwriters to purchase up to 2,045,454 shares within 30 days. The offering is expected to close on March 7, 2023. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers. The funds will support ongoing developments in targeted therapies for RAS-addicted cancers, part of Revolution Medicines' R&D pipeline.
Revolution Medicines, Inc. (Nasdaq: RVMD) has initiated an underwritten public offering to sell up to $300 million of its common stock. The offering includes a 30-day option for underwriters to purchase an additional $45 million worth of shares. The offering is subject to market conditions and might not be completed as proposed. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers for this offering. The company focuses on developing targeted therapies for RAS-addicted cancers, with a robust R&D pipeline centered on RAS(ON) and Companion Inhibitors.
Revolution Medicines (RVMD) reported Q4 2022 financial results, revealing total revenue of $15.3 million versus $9.5 million YoY, primarily from collaboration with Sanofi. This increase was partly due to a non-cash $7.6 million revenue adjustment following the termination of the Sanofi agreement. R&D expenses surged to $66.1 million, reflecting higher clinical trial costs for new drugs RMC-6236 and RMC-6291. The company recorded a net loss of $56.5 million for the quarter. Looking ahead, RVMD anticipates a net loss of $335 to $365 million for 2023. Its pipeline includes several promising RAS(ON) Inhibitors with clinical advancements expected in 2023.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. Senior management will discuss these results and corporate progress during a webcast at 4:30 p.m. Eastern Time. The company is focused on developing targeted therapies for RAS-addicted cancers, with key products in clinical development, including RMC-6236 and RMC-6291. The webcast will also be available as an archived session on its website for at least 14 days.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
What does Revolution Medicines, Inc. specialize in?
What are some of the key products in Revolution Medicines’ pipeline?
What recent achievements has Revolution Medicines reported?
What is the significance of the RMC-6236 Phase 1/1b trial?
How does the merger with EQRx benefit Revolution Medicines?
Who recently joined the board of Revolution Medicines?
What are RAS(ON) inhibitors?
How does Revolution Medicines generate insights for its drug discovery?
What are some of the ongoing trials at Revolution Medicines?
How can investors stay updated on Revolution Medicines’ developments?
